Journal article · 2023 · Open access
In Situ Cocktail Nanovaccine for Cancer Immunotherapy
Advanced Science, 10(31), e2207697 · Published 22 September 2023 · DOI 10.1002/advs.202207697
In brief
“In Situ Cocktail Nanovaccine for Cancer Immunotherapy” is a 2023 journal article by Mohan Liu and 8 co-authors, published in Advanced Science. OpenAlex counts 39 citations as of 21 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Advanced Science.
- Citations
- 39
- Most cited in
- 2025 (21)
- Field-weighted impact
- 3.64
- References
- 67
- Authors
- 9
Abstract
In situ vaccination is a desirable strategy for cancer immunotherapy due to its convenience and capacity to target tumor antigens. Here, an in situ nanovaccine based on a cationic peptide with cholesterol-modified, DP7-C, for cancer immunotherapy is rationally designed, and developed a cancer nanovaccine that is easy to preparate. The nanovaccine includes cocktail small interfering RNAs (siRNAs) and immunologic adjuvant CpG ODNs, has synergistic effect in the cancer treatment. This nanovaccine can induce tumor cell death, promote antigen presentation and relieve immune suppression in the tumor microenvironment (TME). Moreover, this nanovaccine is administered to CT26 (hot) and B16F10 (cold) tumor model mice, in which it targeted the primary tumors and induced systemic antitumor immunity to inhibit metastasis. It is validated that the nanovaccine can convert cold tumors into hot tumors. Furthermore, the nanovaccine increased the immune response to anti-PD-1 therapy by modulating the TME in both CT26- and B16F10-tumor-bearing mice. The siRNA cocktail/CpG ODN/self-assembling peptide nanovaccine is a simple and universal tool that can effectively generate specific tumor cell antigens and can be combined with immuno-oncology agents to enhance antitumor immune activity. The versatile methodology provides an alternative approach for developing cancer nanovaccines.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Liu, M., Xie, D., Hu, D., Zhang, R., Wang, Y., Tang, L., Zhou, B., Zhao, B., & Yang, L. (2023). In Situ Cocktail Nanovaccine for Cancer Immunotherapy. Advanced Science, 10(31), e2207697. https://doi.org/10.1002/advs.202207697
MLA 9
Liu, Mohan, et al. “In Situ Cocktail Nanovaccine for Cancer Immunotherapy.” Advanced Science, vol. 10, no. 31, 2023, p. e2207697. https://doi.org/10.1002/advs.202207697.
Chicago
Liu, Mohan, Daoyuan Xie, Die Hu, Rui Zhang, Yusi Wang, Lin Tang, Bailing Zhou, Binyan Zhao, and Li Yang. 2023. “In Situ Cocktail Nanovaccine for Cancer Immunotherapy.” Advanced Science 10 (31): e2207697. https://doi.org/10.1002/advs.202207697.
Harvard
Liu, M. et al. (2023) ‘In Situ Cocktail Nanovaccine for Cancer Immunotherapy’, Advanced Science, 10(31), p. e2207697. doi:10.1002/advs.202207697.
IEEE
M. Liu et al., “In Situ Cocktail Nanovaccine for Cancer Immunotherapy,” Advanced Science, vol. 10, no. 31, p. e2207697, 2023, doi: 10.1002/advs.202207697.
BibTeX
@article{liu2023situ,
title = {{In Situ Cocktail Nanovaccine for Cancer Immunotherapy}},
author = {Liu, Mohan and Xie, Daoyuan and Hu, Die and Zhang, Rui and Wang, Yusi and Tang, Lin and Zhou, Bailing and Zhao, Binyan and Yang, Li},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {31},
pages = {e2207697},
doi = {10.1002/advs.202207697},
url = {https://doi.org/10.1002/advs.202207697}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 9 | |
| 2025 | 21 | |
| 2026 | 9 |
Its field-weighted citation impact is 3.64: it has been cited 3.64 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- cancer immunotherapy
- CpG oligodeoxynucleotides
- tumor microenvironment
- cold tumor conversion
- hot tumors
- anti-PD-1 therapy
- tumor antigens
- metastasis suppression
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Liu, M., Xie, D., Hu, D., Zhang, R., Wang, Y., Tang, L., Zhou, B., Zhao, B., & Yang, L. (2023). In Situ Cocktail Nanovaccine for Cancer Immunotherapy. Advanced Science, 10(31), e2207697. https://doi.org/10.1002/advs.202207697
How many times has this paper been cited?
39 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Advanced Science: sign in and open the PDF from this page.
Who wrote this paper?
Mohan Liu, Daoyuan Xie, Die Hu, Rui Zhang, Yusi Wang, Lin Tang, Bailing Zhou, Binyan Zhao, Li Yang.
What is the DOI of this paper?
10.1002/advs.202207697, permanently at https://doi.org/10.1002/advs.202207697. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.